UR8 Stock Overview
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
UroGen Pharma Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.50 |
52 Week High | US$21.20 |
52 Week Low | US$7.10 |
Beta | 1.1 |
1 Month Change | -15.63% |
3 Month Change | 0.75% |
1 Year Change | 81.21% |
3 Year Change | -16.15% |
5 Year Change | -58.84% |
Change since IPO | -71.15% |
Recent News & Updates
Recent updates
Shareholder Returns
UR8 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 4.7% | 4.5% | 1.4% |
1Y | 81.2% | 34.0% | 7.5% |
Return vs Industry: UR8 exceeded the German Biotechs industry which returned 31.8% over the past year.
Return vs Market: UR8 exceeded the German Market which returned 5.5% over the past year.
Price Volatility
UR8 volatility | |
---|---|
UR8 Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UR8's share price has been volatile over the past 3 months.
Volatility Over Time: UR8's weekly volatility has decreased from 24% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 200 | Liz Barrett | https://www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
UroGen Pharma Ltd. Fundamentals Summary
UR8 fundamental statistics | |
---|---|
Market cap | €497.65m |
Earnings (TTM) | -€94.62m |
Revenue (TTM) | €76.54m |
6.5x
P/S Ratio-5.3x
P/E RatioIs UR8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
UR8 income statement (TTM) | |
---|---|
Revenue | US$82.71m |
Cost of Revenue | US$9.36m |
Gross Profit | US$73.35m |
Other Expenses | US$175.60m |
Earnings | -US$102.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.00 |
Gross Margin | 88.68% |
Net Profit Margin | -123.61% |
Debt/Equity Ratio | -151.1% |
How did UR8 perform over the long term?
See historical performance and comparison